REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

A Phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536) clinical trials

14/08/2025 23:13:38

rimary registry identifying number	Protocol number
BCTR2019100218	ACE-536-LTFU-001
IOH registration number	
3106/2019	
tudy registered at the country of origin	Study registered at the country of origin: Specify
/es	
ype of registration	Type of registration: Justify
Prospective	N/A
Date of registration in national regulatory	
gency 1/11/2019	
Primary sponsor	Primary sponsor: Country of origin
Selgene Corporation	USA
Date of registration in primary registry	Date of registration in national regulatory agency
2/12/2019	01/11/2019
Public title	Acronym
A Phase 3B, open-label, single-arm, rollover study to evaluate long- erm safety in subjects who have participated in other luspatercept ACE-536) clinical trials	
cientific title	Acronym
Phase 3B, open-label, single-arm, rollover study to evaluate long- erm safety in subjects who have participated in other luspatercept ACE-536) clinical trials	
rief summary of the study: English	
his is a Phase 3b, open-label, single-arm, rollover study for ubjects who have participated in other luspatercept (ACE-536) linical trials. The primary objective is to evaluate the long-term safety (including rogression to acute myeloid leukemia (AML) and/or other nalignancies/pre-malignancies) of luspatercept in subjects who ave participated in other luspatercept clinical trials. Another bjective is to follow subjects for overall survival.	
Brief summary of the study: Arabic	
احد ، والانتقال إلى الأشخاص الذين شاركوا في تجارب سريرية أخرى3دراسة مرحلة (ACE-536) AML)الهدف الأساسي هو تقييم السلامة طويلة الأجل (بما في ذلك التقدم إلى سرطان الدم النخاعي الح المها في الموضوعات الذين مشاركوا في التجارب السريرية Iuspatercept قبل الأورام الخبيثة) م متابعة الموضوعات البقاء على قيد الحياة بشكل ع	و / أو الأورام الخبيئة الأخرى / ماً) (
lealth conditions/problem studied: Specify	

Prior participation on a clinical trial of luspatercept (ACE-536) in protocols eligible for participation in this study ACE-536-LTFU-001 with the following medical conditions:

- Myelodysplastic Syndrome (MDS)

- Beta (β)-thalassemia (THAL)

REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

- Myelofibrosis (MF)

In Lebanon, only patients with beta (β)-thalassemia (THAL) have participated in previuos clinical trial of luspatercept (ACE-536).

Interventions: Specify

Starting as soon as Day 1 of Dose 1 of the rollover protocol, and assessed by the investigator prior to every subsequent treatment dose, subjects may have the dose level increased in a stepwise manner:

□ beyond the starting dose from last dose of luspatercept from the parent protocol up to the defined maximum treatment dose.

□ beyond the starting dose of 1.0 mg/kg in case of subjects crossing over to luspatercept from placebo arm of the parent protocol up to the defined maximum treatment dose.

Key inclusion and exclusion criteria: Inclusion criteria

Subjects must meet ALL the following criteria to be enrolled in this study:

1. Subject is \geq 18 years at the time of signing the informed consent form (ICF).

2. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.

3. Subject has been participating in a luspatercept trial and continues to fulfill all the requirements of the parent protocol and the subject has been either:

a. Assigned to luspatercept treatment, continues to receive clinical benefit in the opinion of the investigator and should continue to receive luspatercept treatment, OR

b. Assigned to placebo arm in the parent protocol (at the time of unblinding or in follow-up) and should cross over to luspatercept treatment, OR

c. Assigned to the Follow-up Phase of the parent protocol, previously treated with luspatercept or placebo in the parent protocol who shall continue into Long-term Post-treatment Follow-up Phase in the rollover study until the follow-up commitments are met (unless requirements are met as per parent protocol to crossover to luspatercept treatment).

4. Subject understands and voluntarily signs an informed consent document prior to any study-related assessments or procedures being conducted.

5. Subject demonstrates compliance, as assessed by the investigator, with the parent study protocol requirements.

6. Applies to on treatment subjects only- females of childbearing potential (FCBP) defined as a sexually mature woman who:

1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months) and must:

a. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the subject practices true abstinence* from heterosexual contact.

b. Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with highly effective, contraception without interruption, 35 days prior to starting investigational product (IP), during the study therapy (including dose interruptions), and for 84 days after discontinuation of study therapy.

7. Applies to on treatment subjects only- Male subjects must:

a. Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 84 days following investigational product discontinuation even if he has undergone a successful vasectomy.

Key inclusion and exclusion criteria: Gender	Key inclusion and exclusion criteria: Specify gender
Both	
Key inclusion and exclusion criteria: Age minimum	Key inclusion and exclusion criteria: Age maximum
18	65
Key inclusion and exclusion criteria: Exclusion criteria	

The presence of any of the following will exclude a subject from enrollment:

1. Applies to on treatment subjects only- Concomitant use of any medications/procedures that are prohibited in the parent luspatercept protocol.

2. Subject has met one or more criteria for study treatment discontinuation as stipulated in the parent luspatercept protocol.

3. First luspatercept transition visit into rollover study > 21 days after end of study (EOS) visit (last dose/visit in case of no EOS visit) of the parent luspatercept study with the exception of those subjects already in the Post-treatment Follow up Phase from the parent study. Note-Subject with current dose delays from the parent protocol during the Transition Phase, will continue in the rollover protocol regardless of the delay.

4. Applies to on treatment subjects only- Pregnant or breastfeeding females.

5. Subject has any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that would prevent the subject from participating in the study.



REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

6. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.

7. Subject has any condition that confounds the ability to interpret data from the study.

Type of study Interventional		
Type of intervention	Type of intervention: Specify ty	/pe
Pharmaceutical	N/A	
Trial scope	Trial scope: Specify scope	
Safety	N/A	
Study design: Allocation	Study design: Masking	
N/A: Single arm study	Open (masking not used)	
Study design: Control	Study phase	
N/A	3	
Study design: Purpose	Study design: Specify purpose	
Treatment	N/A	
Study design: Assignment	Study design: Specify assignm	ent
Single	N/A	
IMP has market authorization	IMP has market authorization:	Specify
No		
Name of IMP	Year of authorization	Month of authorization
Luspatercept (ACE-536)		

Type of IMP

Others

Pharmaceutical class

Luspatercept is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor IIB (ActRIIB) linked to the human immunoglobulin G1 fragment crystallizable (IgG1 Fc) domain. Luspatercept is a homodimeric protein comprised of 2 disulfide-linked polypeptide chains, each with 335 amino acids. Each polypeptide chain contains 3 sites for N-linked glycosylation (total of 6N- linked glycosylation sites per molecule). Peptide mapping and oligosaccharide analysis of luspatercept confirms the presence of highly branched N-linked glycans, typical of a recombinant protein produced in Chinese hamster ovary cells.

Therapeutic indication

 $\begin{array}{l} Myelodysplastic Syndrome (MDS);\\ Beta (\beta)-thalassemia (THAL);\\ Myelofibrosis (MF);\\ Only patients with beta (\beta)-thalassemia (THAL) are applicable in Lebanon\\ \end{array}$


Therapeutic benefit

Luspatercept acts as a ligand trap for Growth Differentiation Factor 11 (GDF11) and other TGF- β family ligands to suppress Smad2/3 signaling. In nonclinical experiments, luspatercept has been shown to bind with high affinity to some TGF- β ligands (eg, GDF11, GDF8, BMP6, and activin B) but substantially less, or not at all, to others (eg, BMP9 and activin A). The mechanism of action of luspatercept is independent from that of erythropoietin. While erythropoietin stimulates proliferation and differentiation of early erythroid progenitors, luspatercept promotes stimulation of the later, maturation phase of erythroblast differentiation and maturation in the bone marrow.

Study model

N/A

Study model: Explain model





Study model: Specify model N/A	N/A
Time perspective N/A Time perspective: Specify perspective N/A	Time perspective: Explain time perspective N/A
Target follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Biospecimen retention None retained	Biospecimen description Not applicable
Target sample size 742	Actual enrollment target size
Date of first enrollment: Type	Date of first enrollment: Date
Anticipated	01/11/2019
Date of study closure: Type	Date of study closure: Date
Anticipated Recruitment status Pending	30/06/2027 Recruitment status: Specify
Date of completion	
IPD sharing statement plan Yes	IPD sharing statement description Patients' full identity will not be on any of the study documents or samples collected and kept by the sponsor for their studies. The partial date of birth will only be collected. Only a unique participant number for the study will link the data or samples to the patients. These data may contain your gender and race, as well as any medical and scientific data required by the study.
Additional data URL	

Admin comments

Â

 \sim



Trial status

Approved

Secondary Identifying Numbers		
Full name of issuing authority	Secondary identifying number	
Food and Drug Administration	IND 112562	

Sources of Monetary or Material Support

Name

Celgene Corporation

Secondary Sponsors Name Not applicable

Contac	Contact for Public/Scientific Queries					
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Aziz Zoghbi	MCT-CRO, Berytech Technology and Health, 5th Floor, Damascus Road, Beirut, Lebanon	Lebanon	009611612 500	zog_az@mct- cro.com	Regional Manager
Scientific	Ali Taher	Chronic Care Center, Hazmieh, Lebanon	Lebanon	009613755 669	ataher@aub.edu. lb	PI

Centers/Hospitals Involved in the Study			
Lenter/Hospital name I Name of principles investigator		Principles investigator speciality	Ethical approval
Chronic Care Center	Dr. Ali Taher	Professor of Medicine, Hematology & Oncology	NA
American university of Beirut	Dr. Ali Taher	Professor of Medicine, Hematology & Oncology	Approved

Ethics Review	Ethics Review			
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Chronic Care Center	30/09/2019	Michele Abi saad	cccmas@chroniccare.org.lb	05 455 103

 \sim



Countries of Recruitment
Name
Lebanon
Bulgaria
Greece
Italy
Thailand
United Kingdom
United States of America
Belgium
Malaysia
Turkey
Australia
France
Germany
Canada
Netherlands
Spain
Sweden
Tunisia
Taiwan

Health Conditions or Problems Studied		
Condition Code K		Keyword
Thalassemia	Thalassaemia (D56)	Thalassemia





Interventions		
Intervention	Description	Keyword
ACE-536	every 3 weeks (Q3W):1.0 mg/kg or same dose as last dose of parent protocol in case IP dose modifications occurred	Treatment Phase

Primary Outcomes			
Name	Time Points	Measure	
Adverse events (AEs)	Enrollment to 42 days post last dose	Type, frequency, severity of AEs, relationship of treatment emergent adverse events to luspatercept	
Development of other malignancies/pre-malignancies	Enrollment to Long-term Post-treatment Follow-up	Number and percentage of subjects developing other malignancies/premalignancies	
Progression to high/very high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) (MDS and myelofibrosis [MF] only). Not applicable for Lebanon patient population consists of B-Thal patients only.	Number and percentage of subjects progressing to high/very high risk MDS or AML	Enrollment to LTPTFU	

Key Secondary Outcomes		
Name	Time Points	Measure
Overall survival	Enrollment to Long-term Post-treatment Follow-up	Time from date of randomization until death from any cause





Trial Results Summary results Study results globally Date of posting of results summaries Date of first journal publication of results Results URL link Baseline characteristics Participant flow Adverse events Outcome measures URL to protocol files